QLS2309 for CD70-positive blood cancers that returned
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new drug called QLS2309 for people with certain blood cancers that have come back or not responded to other treatments. The drug targets a protein called CD70 on the cancer cells, and this study aims to find the safest dose.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a blood cancer that has come back after treatment or hasn't responded to treatment, and your cancer cells have a protein called CD70 on them.
- You must be well enough to be up and about at least half the day (ECOG score 0-2).
- You cannot have had a CD70-targeted treatment before.
- You cannot have active infections like hepatitis B, C, HIV, or syphilis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug (QLS2313) for people with certain blood cancers that have returned or stopped responding to treatment. The drug is given as an injection and may help shrink or control the cancer. This is a phase 1 trial, so the main goal is to find the best dose and see how safe it is.
This trial tests an experimental drug (QLS1209) for advanced solid tumors that have not responded to standard treatments or when no standard treatment exists. The study looks for tumors with certain genetic changes (in CCNE1, FBXW7, or PPP2R1A) and may help guide future treatment options.
This trial tests an investigational drug called QL1706 combined with chemotherapy, given after standard chemoradiation, for people with limited-stage small cell lung cancer. The goal is to see if this combination helps keep the cancer from coming back.
This trial tests a new drug called QL1706 combined with chemotherapy for people with non-small cell lung cancer that has spread or come back after previous treatment with an immunotherapy drug (PD-1/PD-L1 inhibitor) plus chemotherapy. The goal is to see if this combination can help shrink or control the cancer.
This trial tests an experimental drug (called QLS5308) for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug can shrink tumors or slow their growth, and to find the best dose with manageable side effects.
This study tests an experimental drug called QLS5132 for people with advanced solid tumors (cancers that start in organs or tissues). The drug targets a protein called CLDN6 on some cancer cells and might help stop the tumor from growing.
Hear when a new Relapsed or Refractory Hematologic Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.